I want to get continuous structured data on emerging pharmacy benefit management trends and competitor drug pricing strategies from regulatory documents and industry analyst reports.
Gain insights on pharmacy trends and pricing strategies — automated analysis from regulatory documents and reports
A saved example of what you can collect and monitor with Jsonify. Create your own version in Jsonify.
Build this in JsonifyYour original goal is prefilled.
Goal
I want to get continuous structured data on emerging pharmacy benefit management trends and competitor drug pricing strategies from regulatory documents and industry analyst reports.
Source coverage
- pharmacybenefitmanagement.com
- cms.gov
- fda.gov
- drugchannels.com
- ihs.com
- statista.com
- marketresearch.com
- nielsen.com
- medpage.com
- gsk.com
- pfizer.com
- amgen.com
Sample data
Illustrative sample data from the original configuration, not live or verified results.
| id | Source | DocumentTitle | Drug | NegotiatedPrice | Manufacturer | EffectiveDate | Status | Summary |
|---|---|---|---|---|---|---|---|---|
| 1 | cms.gov | Medicare Part D Negotiated Price Update Bulletin | Eliquis (apixaban) 5 mg | $412.50 | Bristol-Myers Squibb | 2026-02-02 | Published | CMS bulletin noting updated negotiated reimbursement benchmark for apixaban under recent Part D pricing rule; reflects increased rebates affecting beneficiary cost share projections. |
| 2 | fda.gov | Advisory: New Labeling Guidance for Oncology Agents | Lumakras (sotorasib) 960 mg | $18,950.00 | Amgen | 2026-02-01 | Guidance | Labeling guidance issued for KRAS G12C inhibitor; includes recommended post-marketing study requirements and safety monitoring; pricing example cited from manufacturer submission. |
| 3 | pharmacybenefitmanagement.com | PBM Quarterly Pricing Trends Report | Humira (adalimumab) 40 mg | $1,725.00 | AbbVie | 2026-01-31 | Analysis | PBM report shows increased net-pricing concessions and shifting formularies; biosimilar uptake cited as driver of reduced net cost for adalimumab in commercial lines. |
| 4 | drugchannels.com | Distribution Margin Pressure: February Brief | Keytruda (pembrolizumab) 100 mg | $14,200.00 | Merck | 2026-02-03 | Report | Industry analysis highlights margin compression across specialty distribution; negotiated buy-and-bill reimbursement trends for immuno-oncology agents discussed. |
| 5 | statista.com | Market Snapshot: Top 20 Specialty Drug Prices | Trikafta (elexacaftor/tezacaftor/ivacaftor) | $32,400.00 | Vertex | 2026-02-04 | Snapshot | Statistical snapshot of list vs. negotiated prices for cystic fibrosis therapies; data show negotiated discounts vary widely by payer and year-to-year contracts. |
| 6 | nielsen.com | Health Products Consumer Price Sensitivity Study | Xarelto (rivaroxaban) 20 mg | $289.00 | Bayer | 2026-02-03 | Survey | Consumer survey finds high price sensitivity for chronic oral anticoagulants; Nielsen models estimate copay assistance alters adherence patterns. |
| 7 | marketresearch.com | Global PBM Competitive Landscape Report | Ozempic (semaglutide) 1.0 mg | $975.00 | Novo Nordisk | 2026-01-30 | Report | Market research on PBM strategies notes preferred formulary placements and step-therapy programs for GLP-1s; negotiated net prices vary by region. |
| 8 | ihs.com | Supply Chain Alert: API Shortage Impact | Valproate (sodium valproate) 500 mg | $48.75 | Generic Consortium | 2026-02-02 | Alert | IHS alert on active pharmaceutical ingredient shortages driving temporary negotiated price increases and allocation measures across wholesalers and PBMs. |
| 9 | medpage.com | Policy Watch: Drug Pricing Transparency Rules | Jardiance (empagliflozin) 25 mg | $210.00 | Boehringer Ingelheim | 2026-02-01 | News | Coverage of new transparency mandates requiring PBMs to publish negotiated rates; commentary on potential market impacts and patient cost sharing. |
| 10 | gsk.com | Investor Presentation: Specialty Portfolio Pricing Update | Nucala (mepolizumab) 100 mg | $4,350.00 | GSK | 2026-02-03 | Presentation | Investor deck lists updated list and negotiated price ranges for respiratory biologics following recent contracting cycles with large PBMs. |
| 11 | pfizer.com | Contracting Notice: Updated Rebate Terms | Ibrance (palbociclib) 125 mg | $9,150.00 | Pfizer | 2026-02-04 | Notice | Manufacturer notice to payers outlining revised rebate schedule and performance-based contracting options tied to progression-free survival metrics. |
| 12 | amgen.com | Pricing Update: Biosimilar Adoption Initiatives | Enbrel (etanercept) 50 mg | $1,100.00 | Amgen | 2026-02-02 | Update | Company update on pricing and contracting incentives to support biosimilar and originator market positioning within PBM formularies. |
| 13 | cms.gov | Medicaid Drug Rebate Program: Guidance Amendment | Spiriva (tiotropium) 18 mcg | $36.40 | Boehringer Ingelheim | 2026-02-03 | Guidance | CMS amends guidance on best-price calculations impacting state Medicaid rebates; example pricing scenarios for inhaled bronchodilators included. |
| 14 | fda.gov | Approval Letter: New Indication Pricing Disclosure | Enhertu (trastuzumab deruxtecan) 5.4 mg/kg | $22,500.00 | AstraZeneca/Daiichi Sankyo | 2026-02-01 | Approval | Approval letter for expanded oncology indication with accompanying sponsor-submitted wholesale acquisition cost and example negotiated price ranges. |
| 15 | pharmacybenefitmanagement.com | PBM Playbook: Formulary Steering Tactics | Dupixent (dupilumab) 300 mg | $3,650.00 | Sanofi/Regeneron | 2026-02-04 | Guide | Practical guide describing step edits, prior authorization criteria, and negotiated rebate structures used to control biologic spend. |
| 16 | drugchannels.com | Wholesaler Pricing Volatility Brief | Remicade (infliximab) 100 mg | $1,980.00 | Janssen | 2026-02-02 | Analysis | Analysis of negotiated buy-and-bill reimbursement variability and effects of biosimilar entrants on contracted prices for infliximab products. |
| 17 | statista.com | Price Index: Oral Oncology Agents | Gleevec (imatinib) 400 mg | $5,420.00 | Novartis | 2026-01-31 | Index | Compiled index showing year-over-year negotiated price movements for oral oncology agents across commercial and Medicare plans. |
| 18 | nielsen.com | Pharmacy Shopper Insights Report | Prolia (denosumab) 60 mg | $1,425.00 | Amgen | 2026-02-03 | Report | Shopper behavior analysis indicating patients switching pharmacies for lower negotiated copays and adherence impact on osteoporosis biologics. |
| 19 | marketresearch.com | US PBM Fee Model Study | Symbicort (budesonide/formoterol) 160/4.5 mcg | $74.99 | AstraZeneca | 2026-02-02 | Study | Study detailing PBM administrative fee arrangements, DIR fee trends, and impact on net paid price for respiratory maintenance inhalers. |
| 20 | ihs.com | Forecast: Sterile Injectable Cost Pressures | Vancomycin IV 1 g | $12.50 | Generic Multiple | 2026-02-04 | Forecast | IHS forecast projects continued pricing pressure on sterile injectables due to contract consolidation and manufacturing capacity shifts. |
| 21 | medpage.com | Analysis: Impact of Copay Accumulator Policies | Xgeva (denosumab) 120 mg | $4,980.00 | Amgen | 2026-02-01 | Analysis | Examination of copay accumulator adoption by payers and PBMs and its downstream effect on patient out-of-pocket for high-cost injectables. |
| 22 | gsk.com | Formulary Access Update: Respiratory Franchise | Nucala (mepolizumab) 100 mg | $4,150.00 | GSK | 2026-02-04 | Update | Company release on updated contracting outcomes with national PBMs to secure preferred formulary placement for eosinophilic asthma therapy. |
| 23 | pfizer.com | Value-Based Contracting Whitepaper | Xeljanz (tofacitinib) 5 mg | $1,350.00 | Pfizer | 2026-01-30 | Whitepaper | Whitepaper describing risk-sharing contract structures and sample negotiated price matrices tied to clinical endpoints for RA therapies. |
| 24 | amgen.com | Pipeline Pricing Strategy Memo | Tezepelumab 210 mg | $7,800.00 | Amgen | 2026-02-02 | Internal Memo | Memo outlining preliminary pricing and contracting assumptions for late-stage asthma biologic ahead of launch, including PBM negotiation scenarios. |
| 25 | cms.gov | CMS Transparency Dashboard Update | Ozempic (semaglutide) 1.0 mg | $825.00 | Novo Nordisk | 2026-02-03 | Published | Dashboard refresh includes recent commercial aggregated negotiated price estimates and payer-level anonymized ranges for diabetes therapies. |
| 26 | fda.gov | Drug Safety Communication: REMS and Cost Considerations | Zolgensma (onasemnogene abeparvovec) | $1,850,000.00 | Novartis | 2026-02-01 | Safety Communication | Safety communication reiterates REMS requirements for gene therapy; sponsor provided representative negotiated contracting structures for government payers. |
| 27 | pharmacybenefitmanagement.com | PBM Contracting Trends: February Brief | Entresto (sacubitril/valsartan) 200 mg | $295.00 | Novartis | 2026-02-04 | Brief | Brief identifies rising use of indication-based pricing clauses and rebates tied to hospitalization reduction metrics for heart failure drugs. |
| 28 | drugchannels.com | Retail Pharmacy Margin Report | Adderall XR (mixed amphetamine salts) 20 mg | $68.00 | Teva | 2026-02-02 | Report | Report on dispensing margins, DIR fee clawbacks, and negotiated reimbursement variability affecting community pharmacies dispensing stimulants. |
| 29 | statista.com | Trend Chart: Biosimilar Price Convergence | Zarxio (filgrastim-sndz) 300 mcg | $285.00 | Sandoz | 2026-02-03 | Chart | Chart documenting narrowing net price differentials between originator and first-wave biosimilars across hospital and outpatient settings. |
Insights and analytics
- Total Regulatory Documents Analyzed (metric)
- Total Competitor Drug Pricing Strategies Reviewed (metric)
- Emerging Trends in Pharmacy Benefit Management Over Time (line)
- Top 5 Competitors by Market Share (bar)
- Distribution of Drug Pricing Strategies (donut)
- Historical Average Drug Prices by Class (area)
- Latest Industry Analyst Reports (table)
- Regulatory Changes Impacting PBM (table)
- Top 10 Emerging PBM Trends (horizontal_bar)
- Key Observations on Pricing Strategies (insights)
- New Drug Pricing Introductions Over Time (line)
- Source Contribution to Insights (pie)
Change notifications
- Price Change Detected — is now $2,500 (+$200) drugchannels.com
- New Listing Appears — is now available pharmacybenefitmanagement.com
- Availability Change — is now unavailable cms.gov
- Coverage Gap Found — missing from latest reports ihs.com
- Offer Structure Changed — now includes new discounts nielsen.com
Integrations and delivery
- snowflake
- api
Make this your own
Start with this goal in Jsonify, then choose the sources and data you need.
Build this in Jsonify